| abstract |
Provided are methods for determining the response of a cancer patient to TOR kinase (mTOR) inhibitors through the measurement of the phosphorylation of PRAS40, GSK3B or p70S6K. Decreased phosphorylation of PRAS40, GSK3B or p70S6K indicates that the TOR kinase inhibitors are active. In an embodiment the TOR kinase inhibitors include compounds of formula (III) or (IV), wherein the variables are as defined in the specification. A preferred TOR kinase inhibitor is 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one. |